Arfolitixorin - Isofol

Drug Profile

Arfolitixorin - Isofol

Alternative Names: 5-10-Methylenetetrahydrofolate; 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; Arfolitixorin; Folitixorin - Isofol; ISO-901; Modufolin; Modulfolin

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Eprova
  • Developer Isofol Medical
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Osteosarcoma
  • Phase I/II Rectal cancer

Most Recent Events

  • 16 May 2018 Isofol Medical plans the pivotal phase III ISO-CC-007 trial for Colorectal cancer (Late-stage disease, Metastatic disease, First-line therapy) in USA and Europe
  • 15 Jan 2018 Updated efficacy data from a phase I/II dose cohort trial in metastatic Colorectal cancer released by Isofol Medical
  • 12 Sep 2017 Adverse events data from a phase I/II trial in Osteosarcoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top